INSTA-Blot Breast Tissue OncoPair

Tissue

Lane	Tissue Type	Cat. No.	Grade	Stage	Sex	Age	Diagnosis
MWM
2	Breast	NBP2-27992	3	IIIA	F	49	Adenocarcinoma
3	Breast	NBP2-27990					Normal adjacent
4	Breast	NBP2-27996	3	II	F	41	Adenocarcinoma
5	Breast	NBP2-27995					Normal adjacent
6	Breast	NBP2-28000	3	IV	F	47	Adenocarcinoma
7	Breast	NBP2-27999					Normal adjacent
8	Breast	NBP2-28004	3	II	F	55	Adenocarcinoma
9	Breast	NBP2-28003					Normal adjacent
10	Breast	NBP2-28008	3	II	F	75	Adenocarcinoma
11	Breast	NBP2-28006					Normal adjacent
12	Breast	NBP2-28012.	3	II	F	53	Adenocarcinoma
13	Breast	NBP2-28011					Normal adjacent
14	Breast	NBP2-28016	3	II	F	60	Adenocarcinoma
15	Breast	NBP2-28015					Normal adjacent

The development of biomarkers has enormous potential for revolutionizing the diagnosis and treatment of disease. Western blot analysis is an integral technique for biomarker profiling. While key for biomarker discovery, the existing body of western blot data has primarily been defined from studies of tumor, immortal, and primary cells growing in vitro. Collectively, results obtained over decades have been integral to the dogma that up- and down-regulation of proteins can be leveraged as biomarkers of normal development, homeostasis, and disease. However, data from human tissue-derived products is key for generating biomarker validation data and progressing the most promising biomarker targets towards the clinic. The OncoPair INSTA-Blot™ product line addresses the increasing demand for the inclusion of human tissue-derived products in biomarker profiling. The OncoPair INSTA-Blot™ is a ready-to-use PVDF western blot membrane containing denatured protein lysates manufactured from Novus extensive Human Clinical Tissue Lysate collection. Each blot contains 14 lanes of alternating tumor (T) and matched normal adjacent (NA) tissue lysates from 7 patient donors. Incorporating both T and NA on the blot enables protein expression analysis of the tumor and microenvironment. The tumor microenvironment is increasingly being recognized as a major factor in influencing malignant progression and metastatic potential. Cancer is a heterogeneous disease and the presence of multiple donors on a single blot enables rapid screening of protein expression variability between T/NA from different individuals and at different disease stages. Clinical diagnosis and histopathology reports from board-certified pathologists are available for every patient sample. OncoPair INSTA-Blots™ are available for a wide range of tumor types and stages. The product line is manufactured from donor patient tissue obtained from established hospital-based collection sites around the world. Tissues are collected under strict bioethical standards using IRB and HIPAA approved protocols. These protocols ensure patient confidentiality, safety, and informed consent. Tissues are flash frozen at collection sites within minutes of removal, maintained in liquid nitrogen and processed into lysates using protocols optimized for extracting proteins from tissues. Lysates are denatured for OncoPair INSTA-Blot™ production; native lysates are available for follow up proteomic studies. OncoPair INSTA-Blots™ and lysates are also useful in conjunction with the Cell Line and Normal Tissue INSTA-Blots™ and lysates for comprehensive antibody validation and to profile antibody reactivity and protein expression patterns across species and between tissues and cells lines. The OncoPair INSTA-Blots™ are proteomic discovery tools and are useful for screening the expression of various proteins in tumor and normal adjacent tissues from various donors. Researchers may want to follow up on their results by further analysis with the corresponding individual lysates when available.